Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Preventing Alcohol Withdrawal Syndrome With Oral Baclofen
NCT02052440 · Denver Health and Hospital Authority · PHASE3 · terminated · last registry update 2018-05-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient funding to complete with low enrollment rate” | – | Registry record, Denver Health and Hospital Authority |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-30Results posted on the registry: Jazz Pharmaceuticals, Xyrem (NCT02221869)
- 2019-03-20Also stopped (terminated): University of Michigan, Multiprofen (NCT03199417)
- 2019-01-08Results posted on the registry: University of North Carolina, Chapel Hill, Baclofen + Placebo (NCT01980706)
- 2018-12-31Also stopped (terminated): Shaare Zedek Medical Center, oral baclofen + placebo + placebo + oral baclofen (NCT00752934)
- 2018-12-19Results posted on the registry: University of Pennsylvania, Baclofen + placebo (NCT01821560)
- 2018-08-14Also stopped (terminated): Wake Forest University Health Sciences, Baclofen + Placebo (NCT01003249)
- 2018-07-24Phase 3 first posted: University Hospital, Montpellier, Sodium Oxybate Oral Solution 500 MG/ML + Placebos (NCT03597555)
- 2018-04-26Results posted on the registry: Washington University School of Medicine, Sodium Oxybate (NCT02063217)
- 2018-03-01Results posted on the registry: Wake Forest University Health Sciences, Baclofen + Placebo (NCT01003249)
- 2018-02-26Results posted on the registry: VA Office of Research and Development, baclofen + Desipramine (NCT01265550)
- 2018-02-23Also stopped (withdrawn): Tufts Medical Center, sodium oxybate + placebo (NCT00744393)
- 2018-02-15Results posted on the registry: MedtronicNeuro, intrathecal baclofen (NCT01032239)
- 2017-11-22Results posted on the registry: Kristina Simonyan, Sodium oxybate (NCT01961297)
- 2017-10-24Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen (NCT03319732)
- 2017-09-25Phase 3 first posted: Kristina Simonyan, Sodium Oxybate (NCT03292458)
- 2017-09-21Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT03290131)
- 2017-08-29Also stopped (withdrawn): Boston Children's Hospital, Baclofen + placebo (NCT01386255)
- 2017-08-24Results posted on the registry: Alliance for Clinical Trials in Oncology, baclofen/amitriptyline/ketamine gel (NCT00516503)
- 2017-08-16Results posted on the registry: National Institute on Alcohol Abuse and Alcoholism (NIAAA), Baclofen (NCT01751386)
- 2017-06-26Phase 3 first posted: University of Michigan, Multiprofen (NCT03199417)
- 2017-06-14Results posted on the registry: University of Pennsylvania, Baclofen + Placebo (NCT02011516)
- 2017-06-01Results posted on the registry: Stanford University, zolpidem tartrate + sodium oxybate (NCT00383643)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision